Sandimmun Neoral: Taiwanese experience in renal transplant patients with special reference to patients with existing liver disease. Transplantation Proceedings 28(3): 1327, 1996
Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplantation Proceedings 28(4): 2232-2233, 1996
Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?. Hepatology 27(6): 1748-1749, 1998
Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Transplantation Proceedings 30(4): 1462-1463, 1998
Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology 2019, 2019
Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement. European Journal of Gastroenterology & Hepatology 28(6): 645-649, 2016
Renal function in liver transplant recipients receiving Neoral versus tacrolimus. Journal of the American Society of Nephrology 7(9): 1926, 1996
The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation 63(11): 1591-1594, 1997
Ursodeoxycholic acid udca treatment improves liver disease and nutritional state in cystic fibrosis cf patients with chronic cholestasis. Gastroenterology 96(5 Part 2): A586, 1989
Efficacy of C0 and C2 monitoring in adult liver transplant recipients treated with neoral, mycophenolate mofetil, and steroids. Transplantation Proceedings 39(10): 3234-3236, 2007
Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy. Journal Of Gastroenterology & Hepatology. 11(4): 385-390, 1996
Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Digestive and Liver Disease 32(4): 318-328, 2001
Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Digestive & Liver Disease 32(4): 318-328, 2000
The effect of ursodeoxycholic acid udca on liver function and bile acid metabolism in patients with cystic fibrosis cf and liver disease. Hepatology 10(4): 726, 1989
Transfer of liver transplant patients from Sandimmun to Neoral. Johnson, R Round Table Series Royal Society of Medicine Press; Rational use of Neoral 30-34, 1996